Reply

Bourdin and Molinari1 suggest that methodological issues may have impacted the robustness and replicability of results described in our article2 that evaluated the relative efficacy of mepolizumab, benralizumab, and reslizumab through an indirect treatment comparison using the Bucher method.3 Specifically, the authors propose that matching-adjusted indirect comparison (MAIC),4 which was recently used in a study by Bourdin et al,5 is more appropriate for accounting for differences in effect modifiers between studies.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2RzYEz1